Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
The reduction of heterodimerization of KOR
2024-08-09

The reduction of heterodimerization of KOR and APJ by both doses of apelin found in the present study may result in inducing protective effects of apelin on the myocardium imposed to high pressure in renovascular hypertension conditions. The finding that apelin in both doses reduced heterodimerizati
-
br Material and methods br Results br
2024-08-09

Material and methods Results Discussion Didox was originally created asa cytostatic drug to inhibit cancer cell proliferation by antagonizing RNR [11]. When used to target highly proliferative cells, Didox has extensive activity in vitro and in vivo. It has also been employed in clinical st
-
Intracellular Signaling Cascades From ligand sensitization t
2024-08-09

Intracellular Signaling Cascades. From ligand sensitization to translation of genes, all cellular processes are dependent on the intracellular levels and activity of partners involved in the signaling pathway. These signaling events lead to critical post-translational modifications including phospho
-
br Introduction Quenchbody Q body immunoassay is
2024-08-09

Introduction Quenchbody (Q-body) immunoassay is a novel biosensing technology that uses the quenching of fluorescence by intrinsic tryptophan (Trp) residues in antibody variable regions when dye(s) are conjugated to an antibody or antibody fragments in appropriate position, and de-quenching while
-
br Experimental procedures br Results br Discussion Our biop
2024-08-09

Experimental procedures Results Discussion Our biophysical and cellular analyses of mutant Aβ1–42 peptides support a role of the N-terminus of Aβ in peptide aggregation and toxicity. We demonstrate that double mutations constructed to humanize the rodent Aβ1–42 sequence result in a signific
-
br Conflict of interest statement br
2024-08-09

Conflict of interest statement Introduction The global prevalence of Alzheimer's disease (AD) is expected to increase to 106 million in 2050 from 30 million in 2010 (Brookmeyer et al., 2007), which will further impose a significant economic burden on health systems and society as a whole (Broo
-
br Conclusion br Conflict of interest br Acknowledgments
2024-08-09

Conclusion Conflict of interest Acknowledgments We thank Nancy Kerkvliet for helpful advice. The research in the lab of CE and THS is supported by the Deutsche Forschungsgemeinschaft (grants ES103/7-1 and 9-1, HA7346/2-1). We apologize to all authors whose work could not be cited due to lim
-
br Conclusion br Conflicts of interest br Introduction
2024-08-08

Conclusion Conflicts of interest Introduction RNA interference is a specific post-transcriptional gene silencing mechanism within a cell via the transfection of microRNAs (miRNA), exogenous small interfering RNAs (siRNA) or small hairpin RNAs (shRNA) [1–3]. Transfection of shRNA can be done
-
br Expression of autotaxin in cancer Autotaxin ATX is
2024-08-08

Expression of autotaxin in cancer Autotaxin (ATX) is a member of the family of NPPs (Nucleotides pyrophosphatases phosphodiesterases (NPP) family with a unique lysophospholipase D (lysoPLD) activity, allowing the synthesis of LPA from lysophospholipid precursors such as the lysophosphatidylcholin
-
NOXA a BH only protein is best known as a
2024-08-08

NOXA, a BH3-only protein, is best known as a selective inhibitor of MCL-1, which is a highly expressed pro-survival protein in many human malignancies [30]. In addition, NOXA was recently proven to act as a direct activator via directly binding to BAX to induce apoptosis [31]. Given that its levels
-
UMI-77 To maintain ATP levels postmortem
2024-08-08

To maintain ATP levels, postmortem muscle mobilizes its glycogen reserves to yield UMI-77 6-phsphate that proceeds through glycolysis. Glycogen degradation was affected by the interaction between treatment and time (P vitro system. While Na-azide can inhibit other ATPases (Bowler et al., 2006, Vasil
-
AR-M 1896 receptor br Materials and methods br Results br Di
2024-08-08

Materials and methods Results Discussion Recently, we showed that stimulation of TRPM3 and TRPC6 channels triggers a signaling cascade leading to the activation of AP-1 [11], [12], [13], [15]. The objective of this study was to investigate whether stimulation of TRPV1 channels leads to an a
-
The most common grade AEs associated
2024-08-08

The most common grade 3/4 AEs associated with the soluble fusion protein ziv-aflibercept are neutropenia, hypertension, and diarrhea [63]. In general, medical oncologists associate ziv-aflibercept with worse toxicity than BV, and meta-analyses of clinical trial data with ziv-aflibercept or BV suppor
-
Based on their different sources the APN inhibitors APNIs
2024-08-07

Based on their different sources, the APN inhibitors (APNIs) can be divided into the natural products and synthetic compounds. Bestatin (1, Fig. 1), isolated from the Streptomyces oliuoreticuli by Umezawa et al., is the first reported and only marketed natural dipeptidomimetic inhibitor of APN. Afte
-
br Development of lorlatinib from
2024-08-07

Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
16231 records 118/1083 page Previous Next First page 上5页 116117118119120 下5页 Last page